HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia
Blocking a specific protein in aggressive leukemia cells restored sensitivity to a modern therapy regardless of mutation status, suggesting a new drug combination worth testing in trials.
HDAC8 is upregulated in KMT2A-rearranged AML and its inhibition degrades STAT3 via acetylation, suppressing MYC and overcoming Venetoclax resistance regardless of TP53 status. HDAC8 inhibitor combination with Venetoclax demonstrated synergistic anti-leukemia activity in primary AML cells, mouse models, and PDX, providing preclinical rationale for clinical trial development in this poor-prognosis AML subtype.
What the study was
- Study design
- Preclinical (KMT2A::MLLT3 mouse model + PDX + primary AML cells)
- Population
- KMT2A-rearranged AML (mouse model, PDX, primary patient cells)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Leukemia
Why it surfaced
Promising TP53-status-independent Venetoclax sensitization in KMT2A-r AML addresses high unmet need; Leukemia journal peer review; PDX validation strengthens translational potential; capped at 5 for preclinical.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.